# Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

> **NCT00683358** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tokyo University** · enrollment: 14 (estimated)

## Conditions studied

- Pancreatic Cancer
- Pancreas Neoplasms

## Interventions

- **BIOLOGICAL:** VEGFR1-A24-1084 (SYGVLLWEI)

## Key facts

- **NCT ID:** NCT00683358
- **Lead sponsor:** Tokyo University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-05
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2009-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683358

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683358, "Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00683358. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*